{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T06:02:56Z","timestamp":1789365776977,"version":"build-2803163510"},"reference-count":28,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"abstract":"\n Aims<\/jats:title>\n Arrhythmic risk is elevated in type 2 diabetes mellitus (T2DM) partly because of abnormal ventricular repolarization. Sodium\u2010glucose cotransporter\u20102 (SGLT\u20102) inhibitors may favourably modify electrophysiological properties beyond their glycaemic effects. We aimed to evaluate the association between dapagliflozin initiation and changes in ECG\u2010derived arrhythmic markers in SGLT\u20102 inhibitor\u2010naive patients with T2DM.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n In this prospective, non\u2010randomized, controlled observational study, 700 T2DM patients (350 dapagliflozin, 350 control) were enrolled between June 2023 and February 2026 at a single tertiary\u2010care center. Dapagliflozin was initiated as part of routine clinical care; controls continued existing antidiabetic therapy. Twelve\u2010lead ECGs and echocardiograms were obtained at baseline and after 3\u2009months. Primary outcomes were changes in QT interval, QTc, QT dispersion, Tp\u2010e interval, Tp\u2010e\/QT ratio and Tp\u2010e\/QTc ratio. All 700 enrolled patients completed 3\u2010month follow\u2010up.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n At 3\u2009months, the dapagliflozin group showed significant reductions in QT (\u22128.8\u2009ms), QTc (\u221210.1\u2009ms), QTd (\u22125.1\u2009ms), Tp\u2010e (\u22126.2\u2009ms), Tp\u2010e\/QT (\u22120.012) and Tp\u2010e\/QTc (\u22120.010) (all\n p<\/jats:italic>\n \u2009<\u2009.001), whereas no clinically meaningful changes occurred in controls. Between\u2010group delta comparisons confirmed significantly greater reductions with dapagliflozin (all\n p<\/jats:italic>\n \u2009<\u2009.001; Cohen's\n d<\/jats:italic>\n : 0.48\u20131.08). Reduction in Tp\u2010e correlated weakly with HbA1c improvement (\n r<\/jats:italic>\n \u2009=\u2009\u22120.145,\n p<\/jats:italic>\n \u2009=\u2009.037,\n r<\/jats:italic>\n 2<\/jats:sup>\n \u2009\u2248\u20092%); the Tp\u2010e\/QT\n vs<\/jats:italic>\n . HbA1c correlation did not reach statistical significance (\n r<\/jats:italic>\n \u2009=\u2009\u22120.147,\n p<\/jats:italic>\n \u2009=\u2009.086). Left ventricular ejection fraction (LVEF) improved modestly (+0.8%,\n p<\/jats:italic>\n \u2009=\u2009.003), and left atrial diameter decreased (\u22120.6\u2009mm,\n p<\/jats:italic>\n \u2009<\u2009.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Three months of dapagliflozin therapy was associated with improvements in multiple ECG\u2010based arrhythmic markers in patients T2DM.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/bcp.70823","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:09:08Z","timestamp":1789362548000},"source":"Crossref","is-referenced-by-count":0,"title":["Effect of dapagliflozin on electrocardiographic arrhythmic markers in patients with type 2 diabetes mellitus"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6198-7270","authenticated-orcid":false,"given":"G\u00fcl\u00fczar","family":"Tra\u015f","sequence":"first","affiliation":[{"name":"Department of Cardiology Mersin City Training and Research Hospital Mersin Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6414-3743","authenticated-orcid":false,"given":"Fuat","family":"Polat","sequence":"additional","affiliation":[{"name":"Department of Cardiology Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Educat\u0131on Research Hosp\u0131tal \u0130stanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7555-1497","authenticated-orcid":false,"given":"Melike","family":"Saday Bozkurt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Adana Kar\u015f\u0131yaka State Hospital Adana Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4735-4634","authenticated-orcid":false,"given":"\u0130smail","family":"Alt\u0131nta\u015f","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Kadirli State Hospital Osmaniye Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,13]]},"reference":[{"issue":"7","key":"e_1_2_11_2_1","first-page":"740","article-title":"Outcomes associated with glucose\u2010lowering drugs in patients with type 2 diabetes and a history of arrhythmia","volume":"19","author":"Becker ML","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03346265"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v3.i8.705"},{"issue":"4","key":"e_1_2_11_5_1","first-page":"335","article-title":"Tp\u2010e interval and Tp\u2010e\/QT ratio as markers of ventricular repolarization: a systematic review","volume":"21","author":"An\u0131l \u00d6zen M","year":"2016","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jelectrocard.2008.07.016"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542\u2010474X.2012.00493.x"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1611925"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15\u20100355"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2018.07.006"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125\u2010016\u20104134\u2010x"},{"issue":"6","key":"e_1_2_11_13_1","first-page":"273","article-title":"SGLT2 inhibitors and cardiac electrophysiology: current evidence","volume":"22","author":"Papazafiropoulou AK","year":"2022","journal-title":"Curr Diab Rep"},{"issue":"1","key":"e_1_2_11_14_1","first-page":"67","article-title":"Effects of SGLT2 inhibitors on QT\/QTc intervals in patients with type 2 diabetes mellitus: a systematic review","volume":"23","author":"Kittipibul V","year":"2023","journal-title":"Am J Cardiovasc Drugs"},{"issue":"23","key":"e_1_2_11_15_1","article-title":"Chronic kidney disease and atrial arrhythmias: new insights into the electrophysiological mechanisms","volume":"21","author":"Russo V","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"e_1_2_11_16_1","first-page":"332","article-title":"Effect of SGLT\u20102 inhibitors on Tp\u2010e interval, Tp\u2010e\/QT and Tp\u2010e\/QTc ratios in type 2 diabetes mellitus patients","volume":"78","author":"\u00d6zt\u00fcrk S","year":"2023","journal-title":"Acta Cardiol"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748\u20101716.2007.01753.x"},{"issue":"3","key":"e_1_2_11_20_1","first-page":"464","article-title":"Advanced glycation end\u2010products decrease HERG channel expression in endothelial cells","volume":"90","author":"Neveu R","year":"2011","journal-title":"Cardiovasc Res"},{"issue":"5","key":"e_1_2_11_21_1","first-page":"295","article-title":"QTc interval and type 2 diabetes mellitus: a cross\u2010sectional study in a Japanese population","volume":"24","author":"Yamaguchi M","year":"2010","journal-title":"J Diabetes Complications"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030183"},{"issue":"7","key":"e_1_2_11_23_1","first-page":"817","article-title":"Excess epicardial adipose tissue impacts on cardiac geometry and function in hypertensive patients with normal body mass index","volume":"20","author":"Mancusi C","year":"2019","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"38","key":"e_1_2_11_24_1","first-page":"3696","article-title":"Effect of empagliflozin on worsening heart failure events in EMPEROR\u2010Preserved Trial","volume":"42","author":"Packer M","year":"2021","journal-title":"Eur Heart J"},{"issue":"4","key":"e_1_2_11_25_1","article-title":"Effect of empagliflozin on QTd and Tp\u2010e intervals in patients with type 2 diabetes and hypertension","volume":"10","author":"Tarcin O","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"issue":"7","key":"e_1_2_11_26_1","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/j.hrthm.2016.05.024","article-title":"J\u2010wave syndromes expert consensus conference report","volume":"13","author":"Antzelevitch C","year":"2016","journal-title":"Heart Rhythm"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933\u2010018\u20100775\u2010z"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.90.2.779"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70823","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70823","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70823","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:09:11Z","timestamp":1789362551000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,13]]},"references-count":28,"alternative-id":["10.1002\/bcp.70823"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70823","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,13]]},"article-number":"bcp.70823"}}